Assessing Phase 2 Data of Tazbentetol in Alzheimer Disease: Bruce Brew, MD, DSc, FRACP, FAAN
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
Early positive signals of cognitive outcomes in mild to moderate Alzheimer patientstreated with the synaptic regenerative small molecule, SPG302 – AAIC 2025 Poster
Inside A Bold New Approach To Alzheimer’s
Enhancing Neurodegenerative Care: Dialogue Exchange with Stella Sarraf of Spinogenix
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
Sydney Alzheimer’s Patients Will Be The First to Trial a New Drug
Hope Pill Will Turn Tables on Dementia
In the News August 8, 2024 By Lisa Wachsmuth— If there was a magic pill to slow the progression of Phil Hazel’s Alzheimer’s disease and allow him to forever retain the happy memories he’s made with his wife Jan, he’d happily swallow it. The Sydney retiree may one day get that chance, with a world-first […]
Synapse-regenerating drug could reverse decline in Alzheimer’s
